Insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) may play an important role in tumor proliferation. This study aimed to investigate the IGF system in children with acute leukemia prior to and after hematological stem cell transplantation (HSCT). In 51 patients (AML n ¼ 27; ALL n ¼ 24; mean age 11.274.8 years), serum parameters (IGF-I,-II, IGFBP-2,-3) were investigated up to 18 months after HSCT by RIA. Patients with AML showed a significant increase of IGFBP-2 up to 100 days after HSCT (mean 7s.d. prior to HSCT: 3.273.6 SDS vs 100 days after HSCT: 5.3173.4 SDS, P ¼ 0.005). Furthermore, IGF-I and IGFBP-3 were significantly decreased (IGF-I: À0.371.5 vs À0.7 71.2 SDS, P ¼ 0.001; IGFBP-3: À0.371.1 vs À1.071.1 SDS, P ¼ 0.02). Children with AML showed significantly higher IGFBP-2 (P ¼ 0.04) and significantly lower IGF-I (P ¼ 0.03) and IGFBP-3 (P ¼ 0.05) levels than children with ALL at day 100 after HSCT. We conclude that children with acute leukemia show important changes in the IGF system after HSCT. In particular, IGFBP-2 was significantly elevated at day 100 after HSCT. Increased IGFBP-2 and decreased IGF-I and IGFBP-3 may be associated with the increased proliferation rate of transplanted bone marrow.
Insulin-like growth factors (IGFs) are a family of peptides strongly associated with cellular growth. Besides the known influence on physiological growth processes and as a parameter for growth-hormone deficiency after polychemotherapy, IGFs effect metabolism and growth of malignant tumors. IGFs are mitogens for a variety of normal and transformed cells. 1, 2 The IGF system consists of two IGF peptides (IGF-I and IGF-II), two receptors, six high-affinity IGF-binding proteins (IGFBPs) and IGFBP cell surface receptors, in addition to IGFBP proteases. 3 Furthermore, at least six low-affinity IGFBP-related proteins (IGFBP-rP), IGFBPrP cell surface receptor proteins and IGFBP-rP proteases have recently been characterized. 4 IGF-I serum concentration is directly associated with growth hormone concentration. It is highly expressed by the liver and other extrahepatic tissues. 5 IGF-II has a lower growth hormone dependency compared to IGF-I. The highest concentrations could be found during the fetal development. 6 Both factors are part of a complex regulation system with both endocrine and paracrine effects on cell growth and regulation. Furthermore, autocrine and intracrine effects have previously been described. 7 In serum and other extracellular fluids, IGFs are combined with high-affinity IGFBPs. 8 In the circulation, more than 99% of IGFs are bound to IGFBP. The serum IGF-I is predominantly found as a 150 kDa tertiary complex that consists of IGF-I, IGFBP-3 and an acidlabile subunit. 9 IGFBPs regulate bioavailability of IGF by increasing or decreasing the affinity to the IGF receptor and by regulation of cellular uptake of IGF. 10 Recently, an IGF-independent action of IGFBPs has also been described.
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A previous study demonstrated significantly increased IGFBP-2 levels in serum of leukemia patients as compared to healthy subjects. Only few data concern changes in the IGF system in children with leukemia after hematological stem cell transplantation (HSCT). This study aims to investigate the changes of IGF-I,-II and IGFBP-2,-3 prior to and after HSCT. By choosing a follow-up time of up to 18 months, a complex overview about these factors could be given.
Patients and methods

Patient population
We investigated IGF-I, IGF-II, IGFBP-2 and IGFBP-3 in 51 consecutive children with AML (n ¼ 27; mean age 13. 675.3 years) and with ALL (n ¼ 24; mean age 11.074.3 years), who underwent bone marrow transplantation (n ¼ 35) or peripheral blood stem cell transplantation (PBSCT) (n ¼ 15). One received both on the same occasion.
In all, 22 patients received autologous HSCT and 29 patients underwent allogeneic HSCT. The donor was HLAidentical related in 14 patients, HLA-matched unrelated in 12 patients, HLA-haploidentical related in two patients and HLA-mismatch unrelated in one patient. Distribution of kind of transplant in 20 relapse-free survivors 18 month after HSCT was similar compared to prior to HSCT (autologous n ¼ 8, allogeneic n ¼ 11, NS, -w 2 test). The demographic conditions of the 51 patients are summarized in Table 1 .
Study design and laboratory investigations
Patients were investigated 20 days prior to, and 30, 60 and 100 days after and 6, 12 and 18 months after HSCT. The decrease in the number of patients at months, 12 and 18 after HSCT is caused by nine children dying within 1 year after HSCT, 19 suffering from relapse (12 AML, seven ALL) and two children not being available for follow-up. All blood samples used were residues from routine laboratory measurements. Blood samples for determination of the IGF parameters and binding proteins were frozen at À701C until measurement. The following parameters were investigated.
Serum measurements
IGFBP-2 levels in serum were analyzed by RIA with a commercial system (DSL, Webster, TX, USA) as described. 12 Diluted samples were incubated with polyclonal anti-IGFBP-2 antibody and 125 I-IGFBP-2 for 20 h at 41C. Separation of the bound fraction was accomplished by addition of a second antibody and polyethylene glycol. The lower limit of detection was 0.5 ng/ml. Intra-assay coefficient of variation was 5.7% and interassay coefficient of variation was 6.3%.
IGF-I analyses were performed, after acid-ethanol extraction, by radioimmunoassay (RIA; Biochem Immumosystems, Freiburg, Germany). The sensitivity limit of this assay was 12 ng/ml. Intra-and interassay coefficient of variation was 3.8 and 5.1%.
IGF-II and IGFBP-3 were analyzed by immunoradiometric assay (IRMA; DSL, Webster, TX, USA). The sensitivity limits of these assays were lower than 40 ng/ml for IGF-II and 0.5 ng/ml for IGFBP-3. Intra-and interassay coefficients of variation were 3.8 and 6.5% for IGF-II and 6.2 and 6.8% for IGFBP-3.
Statistics
All values are presented as the mean and s.d. of the age and sex-independent standard deviation score (SDS). Statistical significance was judged by a P-value of o0.05. Statistical procedures were performed using SPSS for windows version 10.13 (SPSS Inc., Chicago, IL, USA). The statistical difference between values of two independent groups was tested by the Mann-Whitney-Wilcoxon test. The Wilcoxon match-pairs signed-rank test was used to compare the results prior to and after HSCT. All investigations were strictly made in accordance with the guidelines of the local ethics committee.
Results
Patients with acute leukemia showed a continuous increase of IGFBP-2 and at the same time a decrease of IGF-I and IGFBP-3 up to day 100 after HSCT ( Figures 1, 3 and 4) . Moreover, ALL patients had a significant increase in IGFBP-2 serum levels up to day 100 (prior to HSCT: 2.672.9 vs 3.873.2 SDS, P ¼ 0.02). There was a trend Table 2 and Figures 1, 3 and 4.
The serum levels of IGFBP-2, IGF-I and IGFBP-3 were different in AML and ALL. It was demonstrated that children with AML had significantly higher IGFBP-2 (P ¼ 0.04) and significantly lower IGF-I (P ¼ 0.03) and IGFBP-3 (P ¼ 0.05) levels than children with ALL at day 100 after HSCT. Otherwise, patients with AML and ALL showed significantly increased IGFBP-2 serum concentrations at day 100 after HSCT compared to normal levels (AML: Po0.001; ALL: P ¼ 0.02; Figure 3 ). The type of transplantation (autologous vs allogeneic) had no influence on the demonstrated changes of the IGF system neither in AML nor ALL. Furthermore, no correlation was visible between IGF-and IGFBP serum levels and acute or chronic graft-versus-host disease (GvHD).
Discussion
During the last years, significant changes of the IGF factors and IGF-binding proteins have been found in association with several tumors as well as leukemia. [13] [14] [15] [16] To our knowledge, we present for the first time results that show the changes of insulin-like growth factors and their binding protein during long-term follow-up after stem cell transplantation. 17, 18 Especially, the significant increase of IGFBP-2 serum levels up to 100 days after transplantation has never been shown before. About 89% (n ¼ 24) of patients with AML and 66% (n ¼ 16) of ALL patients showed increased serum concentration greater than +2 SDS at day 100 (in some cases up to five times greater than the normal levels at day 100). An increase of IGFBP-2 expression might be directly correlated to the increased cell proliferation rates has been reported. 19 Human cell lines with IGFBP-2 expression showed higher tumorigenicity compared to cell lines without or lower IGFBP-2 expression. These data are confirmed by Mohnike et al, 20 who investigated children with leukemia at the time of diagnosis. They found increased IGFBP-2 values at the time of diagnosis and a normalization during remission. It is assumed that an increased IGFBP-2 expression might have a regulatory effect on the local IGF bioavailability. Besides a storage function, a transport function of IGFBPs has also been described. Binary complexes (IGF-I-IGFBP-2 complex) may enter the capillary barrier. 21 By this mechanism, IGF can be transported into the cell. Another possible model emphasizes a reactive overproduction of IGFBP-2 in malignant tumors, caused by a reduced ability of IGF analogs to form complexes with locally produced IGFBPs. 22 However, it is known that children suffering from acute leukemia show higher serum levels of IGFBP-2 as well as an increased expression of IGFBP-2 mRNA compared to healthy children. 23, 24 Owing to the markedly high IGFBP-2 serum concentrations during fetal development, it may be speculated that the increase of IGFBP-2 is related to the proliferation of early progenitor cells. 25 Furthermore, a direct proliferative effect of IGFBP-2 is assumed and might be involved in the bone marrow recovery. 26 On the other hand, the significant increase of IGFBP-2 was accompanied by a decrease of IGF-I and IGFBP-3. Lower IGFBP-3 concentrations are associated with a * * * * * * * * * * Changes of serum growth factors prior to and after SCT K Dawczynski et al higher risk of malignancy. 27 Otherwise, elevated IGFBP-3 is positively associated with the survival of children with childhood leukemia. 28 Recent studies have indicated that IGFBP-3 may also have an antiproliferative and growth inhibitory effect through induction of the tumor suppressor gene p53. 29, 30 According to our results with decreased IGFBP-3 serum concentrations, it is reasonable to speculate that IGFBP-3 acts as a factor in tumor proliferation and development. Moreover, it is known that catabolic metabolism, liver dysfunction, acidosis, burning and systemic infections are associated with low IGF-I and IGFBP-3 serum concentration. [31] [32] [33] [34] [35] These possible influence factors should be considered in all interpretations. However, our measured IGF and IGFBP changes are much higher than the described changes in these conditions. Furthermore, a significant influence of the therapeutic regime seems to be unlikely, because we found the changes of the IGF system in nearly all patients independent of their different conditioning regimen (Table 3) .
Moreover, patients with AML showed a significant increase of IGFBP-2 serum levels accompanied by a decrease of IGF-I and IGFBP-3 serum levels. The same was true with regard to the ALL patients. As a result of the high individual scatter and the small number of samples in the groups, no statistical significance could be demonstrated. The different IGFBP-2 values in AML and ALL patients cannot be explained at this time. In conclusion, this study provides strong evidence for changes of the IGF system in children with acute leukemia during long-time follow-up after HSCT. IGFBP-2 especially was found to be significantly elevated up to 100 days after HSCT. One the other hand, there was a decrease of IGF-I and IGFBP-3. These results suggest a possible involvement of IGF-I in childhood acute leukemia, but further studies are necessary to establish whether IGFBP-2 plays a role in this disease after HSCT. 
